Drug Trial Radar · NCT04363242
A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions
Last checked: Nov 19, 2026Latest source record: Apr 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
22
Actual
Start
Apr 9, 2020
Primary completion
Jul 31, 2023
Study completion Sep 30, 2023
Sponsor
- Lead sponsor
- Synermore Biologics Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Synermore Biologics USA Limited
- First posted
- Apr 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1 Dose Escalation Trial of SYN125 Single Agent in the Treatment of Solid Tumors and in Combination With Fixed Dose SYN004 in Patients With Cancer of the Internal or External Lining of the Body.
Conditions
- Epithelial Carcinoma
- Solid Tumor
Interventions
SYN125Biological
Administered by IV infusion
SYN004Biological
Administered by IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Incidence of dose-limiting toxicities (DLTs)Time frame: Up to Day 28
- Part B: Incidence of dose-limiting toxicities (DLTs)Time frame: Up to Day 28
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of Kansas Cancer Center, Clinical Research Center, 4350 Shawnee Mission Parkway, MS 6004
Fairway, Kansas
Henry Ford Health System, Henry Ford Hospital
Brownstown, Michigan
Washington University School of Medicine
St Louis, Missouri
University of Oklahoma, Peggy and Charles Stephenson Cancer Center, 800 Northeast 10th Street
Oklahoma City, Oklahoma
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.